Guardian Wealth Advisors (North Carolina)’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-3
Closed -$12.5K 444
2023
Q2
$12.5K Hold
3
﹤0.01% 335
2023
Q1
$7.23K Hold
3
﹤0.01% 349
2022
Q4
$7.1K Hold
3
﹤0.01% 327
2022
Q3
$10K Buy
+3
New +$11.8K ﹤0.01% 290

Other funds holding SEEL

Guardian Wealth Advisors (North Carolina)'s SEEL Position: Q3 2023 in Review

Guardian Wealth Advisors (North Carolina) sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 3 shares — an estimated $12.5K sold.

Guardian Wealth Advisors (North Carolina) first reported a position in SEEL in Q3 2022 and held it in 4 quarters. The position peaked at $12.5K in Q2 2023. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

  • Guardian Wealth Advisors (North Carolina) reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Guardian Wealth Advisors (North Carolina) sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.5K.
  • Guardian Wealth Advisors (North Carolina) first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Guardian Wealth Advisors (North Carolina)'s Seelos Therapeutics, Inc. Common Stock position peaked at $12.5K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Guardian Wealth Advisors (North Carolina)'s 13F filing for Q3 2023, filed 14 Nov 2023.